Proquest Dissertations

Total Page:16

File Type:pdf, Size:1020Kb

Proquest Dissertations The chemotherapeutic consequences of tumor pH in breast carcinoma model systems Item Type text; Dissertation-Reproduction (electronic) Authors Mahoney, Brent P. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 06/10/2021 04:25:37 Link to Item http://hdl.handle.net/10150/280195 INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overiaps. ProQuest Information and Learning 300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA 800-521-0600 THE CHEMOTHERAPEUTIC CONSEQUENCES OF TUMOR pH IN BREAST CARCINOMA MODEL SYSTEMS By Brent Paul Mahoney CopjTight © Brent Paul Mahoney 2002 A Dissertation Submitted to the Facuhy of the GRADUATE INTERDISCIPLINARY PROGRAM IN CANCER BIOLOGY In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2002 UMI Number: 3073244 Copyright 2002 by Mahoney, Brent Paul All rights reserved. 0 UMI UMI Microform 3073244 Copyright 2003 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Infonmation and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor. Ml 48106-1346 2 THE UNIVERSITY OF ARIZONA ® GRADUATE COLLEGE As members of the Final Examination Committee, we certify that we have read the dissertation prepared by Brent P. Mahoney entitled The r.hemotherappnM'p rnngpgiipnppg of Tnmny pH in r.arc-innma Model SvsI-pitir and recommend that it be accepted as fulfilling the dissertation Moment for the Degree of Philosophy Robe Date ;tc William Bella Harris Bernstein Date Date Final approval and acceptance of this dissertation is contingent upon the candidate's submission of the final copy of the dissertation to the Graduate College. I hereby certify that I have read this dissertation prepared under my dix^cc^ens^and recommend that it be accepted as fulfilling the dissertation f^iremet JjItiLi. Disse: ion D pr Robert Gillies Date^ 3 STATEMENT BY AUTHOR This dissertation has been submitted in partial fulfillment of requirements for an advanced degree at The University of Arizona and is deposited in the University Library to be made available to borrowers under rules of the Library. Brief quotations from this dissertation are allowable without special permission, provided that accurate acknowledgment of source is made. Requests for permission for extended quotation from or reproduction of this manuscript in whole or in part may be granted by the copyright holder. 4 ACKNOWLEDGMENTS I would first and foremost like to acknowledge my graduate advisor, Dr. Robert J. Gillies, for his support and supervision of this research. I thank Dr. Gillies for his mentoring, providing both support and guidance during our many scientific discussions about this project. I would also like to thank my committee members for all of their advice during committee meetings; Dr. William Bellamy, Dr. Charles Taylor, Dr. Harris Bernstien, and Dr. Janet Decker. I would particularly like to Dr. Bellamy and Dr. Taylor for providing helpful discussions and technical assistance for this work. I would like to thank the entire Gillies laboratory for the lively intellectual discussions and useful technical advice during weekly lab meetings. I especially thank Brenda Baggett for her technical assistance over the years; Dr. Paul Schornack and Charles Fahr for their input on my research during our group meetings; Dr. Natarajan Raghunand for his assistance with the NMR and animal studies; and Xi He, Dr. Natarajan Raghunand, Dr. Paul Schornack, Charles Fahr, Dave Morse and Dr. Nancy Aiken for their contributions during discussions about this work. I would like to thank Anne Cione and Merry Warner for providing secretarial assistance. I would also like to acknowledge Ron Lynch and Jesse Martinez for their helpful advice during scientific discussions. I thank all of my colleagues in the Arizona Cancer Center for making the basement an enjoyable place to work. 5 DEDICATION To my parents Brian and Linda Mahoney and my wife Dr. Paula Inserra-Mahoney. Your love, encouragement, guidance and support will never be forgotten, I would also like to dedicate this dissertation to my grandmother Angela Mahoney who passed away form pancreatic cancer February 7, 1999. 6 TABLE OF CONTENTS LIST OF FIGURES 9 ABSTRACT 15 I - INTRODUCTION - A REVIEW OF THE LITERATURE 17 A) An Overview of Breast Cancer 17 B) Chemotherapy and Breast Cancer 19 C) Characterization of Chemotherapeutic Drugs and their pH Dependent Behavior.— 21 i) Doxorubicin 22 ii) Daunorubicin 30 iii) Mitoxantrone 35 iv) Paclitaxel 41 V) Vincristine „..4 6 vi) Vinblastine 50 vii) Cyclophosphamide 5 5 viii) Chlorambucil 62 ix) 5-Fluorouracil 67 D) Tumor pH - Observations and Measurements.— 73 E) Causes of Acidic Tumor pH 75 F) Modulators of Tumor pH in vivo. 77 G) Consequences of Tumor Acidity 78 H) Ionizing Radiation Therapy and Tumor pH 81 I) Hypothermic Therapy and Tumor pH 83 J) Tumor pH as a Novel Therapeutic Target 85 K) Cancer Genes and Tumor pH 87 L) V-ATPase Can Inhibit Apoptosis 88 M) Apoptosis and Cell Cycle Blockade 89 II - MATERIALS AND METHODS 92 a) Cell and Tiomor Growth 92 b) Magnetic Resonance Spectroscopy 92 c) Measurement of Octanol Partition Coeffecient94 d) Measurement of Intracellular pH In Vitro. 95 e) D r\xg Upta ice..H.».......»..*.».......•...... *96 f) Drug Cytotoxicity 97 7 g) Calculation of Theoretical Drug Distributions 97 h) Tumor Growth Statistics 98 i) Doxorubicin Biodistribution in MCF-7 Mammary Tumor Bearing SCID Mice 99 j) Doxorubicin Biodistribution in C3H Mammary Tumor Bearing C3H/hen Mice 102 k) Mitoxantrone Biodistribution in C3H Mammary Tumor Bearing C3H/hen Mice 104 1) C3H/hen Mouse-C3H Mammary Carcinoma Model. 106 m) Gavage Administration of NaHC03/NH4Cl 107 n) Intraperitoneal Administration of NaHCOa/Glucose 107 o) Localized in vivo MR Spectroscopy 108 p) Chemotherapy 109 III - ION TRAPPING AND THE CHEMOTHERAPEUTIC CONSEQUENCES OF EXTRACELLULAR pH MODULATION IN VITRO... Ill Introduction Ill Results 118 Theoretical Drug Distribution 118 Characterization of the MCF-7 In Vitro Model System 126 In Vitro Drug Accumulation 130 In Vitro Drug Accumulation in Resistant Model Systems 134 In Vitro Toxicity 141 Discussion 161 IV - THE PHARMACOKINETIC CONSEQUENCES OF METABOLIC ALKALOSIS ENHANCED CHEMOTHERAPY WITHIN IN VIVO BREAST CARCINOMA MODEL SYSTEMS 161 Irrtro^iuctjLon.•...• 161 Results 161 MCF-7 Tumor pH Modulation by Chronic Sodium Bicarbonate Ad Librixim In SCID Mice 163 Acute Modulation of C3H Mammary Carcinoma Tumor pH in C3H/hen Mice with B^carbona t • • • • 166 The Effect of Chronic 200 mM Ad Librium Sodium Bicarbonate Administration on MCF-7 Tumor Growth in SCID Mice 181 The Effect of Acute Alkalization, via Intraperitoneal Injection of 0.7 ml 8- of a IM NAHCO3, on the Growth Rate of C3H Mammary Carcinoma in C3H/hen Mice 184 The Effect Of Chronic Metabolic Alkalosis On Doxorubicin's Anti-Tumor Activity in the MCF-7 Human Mammary Carcinoma In Vivo Model System 187 Acute Alkalization with Bicarbonate Enhances Mitoxantrone's Anti-Tumor Activity in C3H Mammary Carcinoma In Vivo. 192 The Effect Of Our Acute Tumor Alkalization Protocol, i.e. the Intraperitoneal Injection of 0.7 ml of a IM NaHC03, on Dose Limiting Toxicity to the Host, C3H/Hen Mice 200 The Effect Of Acute Tumor Alkalinization Via Intraperitoneal Injection of 0.7 ml Of IM NaHCOa, On Paclitaxels C3H Mammary Carcinoma Anti-Tumor Activity In C3H/Hen Mice 209 Discussion 217 V - THE EFFECT OF METABOLIC ALKALOSIS ON DRUG BIODISTRIBUTION IN VIVO 223 Introduction ..223 Results 227 Mitoxantrone Biodistribution in C3H Mammary Tumor Bearing C3H/hen Mice 227 Doxorubicin Biodistribution in MCF-7 Mammary Tumor Bearing SCID Mice 243 Doxorubicin Biodistribution in C3H Mammary Tumor Bearing C3H/hen Mice 259 Discussion.™ 275 VI - CONCLUSIONS 280 VII - REFERENCES 284 9 LIST OF FIGURES Figure 1.1 Doxorubicin 29 Figure 1.2 Daunorubicin 34 Figure 1.3 Mitoxantrone 40 Figure 1.4 Paclitaxel 45 Figure 1.5 Vincristine 49 Figure 1.6 Vinblastine 54 Figure 1.7 Cyclophosphamide 61 Figure 1.8 Chlorambucil 66 Figure 1.9 5-Flourouracil 72 Figure 3.1 Predicted Partitioning of Mitoxantrone (pKa =8.2) 121 Figure 3.2 Predicted Partitioning of Chlorambucil (pKa = 5.8) 122 Figure 3.3 ^'*C Doxorxabicin Partition Coeffecient 123 Figure 3.4 Flourescent Measurement of Doxoriibicin's Partition Coeffecient 124 Figure 3.5 ^"'c Mitoxantrone Partition Coeffecient ..125 Figure 3.6 MCF-7 Cell Density Following Either Acid or Base Exposure..~.M....M.n............................M................u.......M.......~....... 128 Figure 3.7 Intracellular pH of MCF-7 Cells as a Fxinction of Extracellular pH 129 Figure 3 .8 In vitro "c Doxorxibicin Accumulation in P^^«»F 7 11 S .....M....M.».M....H....n.......»....m.M....»..........M.............M.M...........• 13 2 Figure 3 .9 In Vitro ^"^C Mitoxantrone Accumulation in MCF-7 Cells 133 10 Figure 3,10 In.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti Et Al
    US008580267B2 (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti et al. (45) Date of Patent: Nov. 12, 2013 (54) IMMUNOCYTOKINES FORTUMOUR (56) References Cited THERAPY WITH CHEMOTHERAPEUTIC AGENTS FOREIGN PATENT DOCUMENTS (75) Inventors: Marta Pedretti, Zurich (CH): Dario WO O2/O59264 8, 2002 WO O3,O93478 11, 2003 Neri, Buchs (CH) WO 2004/OO2528 1, 2004 WO 2006/026020 3, 2006 (73) Assignee: Philogen S.p.A., Siena (IT) WO 2006/050834 5, 2006 WO 2007/128563 11, 2007 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Paul, William, Fundamental Immunology, 3rd Edition, Raven Press, New York, 1993, pp. 292-295.* (21) Appl. No.: 13/139,655 Vajdos et al., Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning 1-1. mutagenesis. J. Mol. Biol. 320:415-428, 2002.* (22) PCT Filed: Dec. 14, 2009 Bartolomei, M., et al. “Combined treatment of glioblastomapatients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and (86). PCT No.: PCT/EP2009/008920 temozolomide.” QJNuclMed Mol Imaging. Sep. 2004:48(3):220-8. S371 (c)(1) Marlind, J., et al. "Antibody-mediated delivery of interleukin-2 to the (2), (4) Date. Jun. 14, 2011 Stroma of breast cancer strongly enhances the potency of chemo s 9 therapy” Clin Cancer Res. Oct. 15, 2008;14(20):6515-24. Brack, S.S., et al. “Tumor-targeting properties of novel antibodies (87) PCT Pub. No.: WO2010/078916 specific to the large isoform oftenascin-C.” Clin Cancer Res.
    [Show full text]
  • Ep 2569287 B1
    (19) TZZ _T (11) EP 2 569 287 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 413/04 (2006.01) C07D 239/46 (2006.01) 09.07.2014 Bulletin 2014/28 (86) International application number: (21) Application number: 11731562.2 PCT/US2011/036245 (22) Date of filing: 12.05.2011 (87) International publication number: WO 2011/143425 (17.11.2011 Gazette 2011/46) (54) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERBINDUNGEN ALS HEMMER DER ATR-KINASE COMPOSÉS UTILISABLES EN TANT QU’INHIBITEURS DE LA KINASE ATR (84) Designated Contracting States: • VIRANI, Aniza, Nizarali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abingdon GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oxfordshire OX144RY (GB) PL PT RO RS SE SI SK SM TR • REAPER, Philip, Michael Abingdon (30) Priority: 12.05.2010 US 333869 P Oxfordshire OX144RY (GB) (43) Date of publication of application: (74) Representative: Coles, Andrea Birgit et al 20.03.2013 Bulletin 2013/12 Kilburn & Strode LLP 20 Red Lion Street (73) Proprietor: Vertex Pharmaceuticals Inc. London WC1R 4PJ (GB) Boston, MA 02210 (US) (56) References cited: (72) Inventors: WO-A1-2010/054398 WO-A1-2010/071837 • CHARRIER, Jean-Damien Abingdon • C. A. HALL-JACKSON: "ATR is a caffeine- Oxfordshire OX144RY (GB) sensitive, DNA-activated protein kinase with a • DURRANT, Steven, John substrate specificity distinct from DNA-PK", Abingdon ONCOGENE, vol. 18, 1999, pages 6707-6713, Oxfordshire OX144RY (GB) XP002665425, cited in the application • KNEGTEL, Ronald, Marcellus Alphonsus Abingdon Oxfordshire OX144RY (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Paycheck Protection Program Loans
    Paycheck Protection Program Loans Loan Amount Business Name Headquarters City a $5-10 million ABO LEASING CORPORATION PLYMOUTH a $5-10 million ACMS GROUP INC CROWN POINT a $5-10 million ALBANESE CONFECTIONERY GROUP, INC. MERRILLVILLE a $5-10 million AMERICAN LICORICE COMPANY LA PORTE a $5-10 million AMERICAN STRUCTUREPOINT, INC. INDIANAPOLIS a $5-10 million ASH BROKERAGE, LLC FORT WAYNE a $5-10 million ASHLEY INDUSTRIAL MOLDING, INC. ASHLEY a $5-10 million BEST CHAIRS INCORPARATED FERDINAND a $5-10 million BIOANALYTICAL SYSTEMS, INC. WEST LAFAYETTE a $5-10 million BLUE & CO LLC CARMEL a $5-10 million BLUE HORSESHOE SOLUTIONS INC. CARMEL a $5-10 million BRAVOTAMPA, LLC MISHAWAKA a $5-10 million BRC RUBBER & PLASTICS INC FORT WAYNE a $5-10 million BTD MANUFACTURING INC BATESVILLE a $5-10 million BUCKINGHAM MANAGEMENT, L.L.C. INDIANAPOLIS a $5-10 million BYRIDER SALES OF INDIANA S LLC CARMEL a $5-10 million C.A. ADVANCED INC WAKARUSA a $5-10 million CFA INC. BATESVILLE a $5-10 million CINTEMP INC. BATESVILLE a $5-10 million CONSOLIDATED FABRICATION AND CONSTRUCTORS INC GARY a $5-10 million COUNTRYMARK REFINING & LOGISTICS LLC MOUNT VERNON a $5-10 million CROWN CORR, INC. GARY a $5-10 million CUNNINGHAM RESTAURANT GROUP LLC INDIANAPOLIS a $5-10 million DECATUR COUNTY MEMORIAL HOSPITAL GREENSBURG a $5-10 million DIVERSE STAFFING SERVICES, INC. INDIANAPOLIS a $5-10 million DRAPER, INC. SPICELAND a $5-10 million DUCHARME, MCMILLEN & ASSOCIATES, INC. FORT WAYNE a $5-10 million ELECTRIC PLUS, INC AVON a $5-10 million ENVIGO RMS, LLC INDIANAPOLIS a $5-10 million ENVISTA, LLC CARMEL a $5-10 million FLANDERS ELECTRIC MOTOR SERVICE INC EVANSVILLE a $5-10 million FOX CONTRACTORS CORP FORT WAYNE a $5-10 million FUSION ALLIANCE, LLC CARMEL a $5-10 million G.W.
    [Show full text]
  • AXS TV Schedule for Mon. September 10, 2012 to Sun. September 16, 2012 Monday September 10, 2012
    AXS TV Schedule for Mon. September 10, 2012 to Sun. September 16, 2012 Monday September 10, 2012 4:30 PM ET / 1:30 PM PT 6:00 AM ET / 3:00 AM PT Nothing But Trailers IMAX - Grand Canyon Adventure - River at Risk Sometimes the best part of the movie is the preview! So HDNet presents a half hour of Noth- Narrated by Academy Award®-winning filmmaker, actor, and noted environmentalist Robert ing But Trailers. See the best trailers, old and new in HDNet’s collection. Redford. Follow the great Colorado River as it reveals the most pressing environmental story of our time - the world’s growing shortage of fresh water. 5:00 PM ET / 2:00 PM PT Hustle 7:00 AM ET / 4:00 AM PT Mickey and the team are thrust into a daring daylight heist to retrieve stolen diamonds that Hustle are hidden beneath a police station and wanted back by the owner. Mickey and the team are thrust into a daring daylight heist to retrieve stolen diamonds that are hidden beneath a police station and wanted back by the owner. 6:00 PM ET / 3:00 PM PT JAG 8:00 AM ET / 5:00 AM PT Fighting Words - While respected and decorated Marine General Earl Watson has been as- Honky Tonk TV: Your Country signed to lead the joint task force charged with capturing all the remaining high-value targets This week we’ve got Lee Brice and Colt Ford. Our girl Roxy chats with JT Hodges and he in Iraq, a troubling revelation surfaces.
    [Show full text]
  • Aspects of the Usage of Antineoplastic and 1Mmunomodulating Agents in a Section of the Private Health Care Sector
    ASPECTS OF THE USAGE OF ANTINEOPLASTIC AND 1MMUNOMODULATING AGENTS IN A SECTION OF THE PRIVATE HEALTH CARE SECTOR Wilmarie Rheeders B. Pharm Dissertation submitted in Pharmacy Practice, School of Pharmacy at the Faculty of Health Sciences of the North-West University, Potchefstroom, in partial fulfilment of the requirements for the degree Magister Pharmaciae. Supervisor: Prof M.S. Lubbe Co-supervisor: Dr. J.L. Duminy Co-supervisor: Prof. M.P. Stander Potchefstroom November 2008 For all things are from Him, by Him, and for Him. Glory belongs to Him forever! Amen. (Rom. 11:36) ACKNOWLEDGEMENTS To my Lord and Father whom I love, all the Glory! He gave me the strength, insight and endurance to finish this study. 1 also want to express my sincere appreciation to the following people that have contributed to this dissertation: • To Professor M.S. Lubbe, in her capacity as supervisor of this dissertation, my appreciation for her expert supervision, advice and time she invested in this study. • To Dr. J.L Duminy, oncologist and co-supervisor, for all the useful advice, assistance and time he put aside in the interest of this dissertation. • To Professor M.P. Stander, in his capacity as co-supervisor of this study. • To Professor J.H.P. Serfontein, for his guidance, time, effort and advice. • To the Department of Pharmacy Practice as well as the NRF for the technical and financial support. • To Anne-Marie, thank you for your patience, time and continuous effort you put into the data. • To the Pharmacy Benefit Management company for providing the data for this dissertation.
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]
  • Multistage Delivery of Active Agents
    111111111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (io) Patent No.: US 10,143,658 B2 Ferrari et al. (45) Date of Patent: Dec. 4, 2018 (54) MULTISTAGE DELIVERY OF ACTIVE 6,355,270 B1 * 3/2002 Ferrari ................. A61K 9/0097 AGENTS 424/185.1 6,395,302 B1 * 5/2002 Hennink et al........ A61K 9/127 (71) Applicants:Board of Regents of the University of 264/4.1 2003/0059386 Al* 3/2003 Sumian ................ A61K 8/0241 Texas System, Austin, TX (US); The 424/70.1 Ohio State University Research 2003/0114366 Al* 6/2003 Martin ................. A61K 9/0097 Foundation, Columbus, OH (US) 424/489 2005/0178287 Al* 8/2005 Anderson ............ A61K 8/0241 (72) Inventors: Mauro Ferrari, Houston, TX (US); 106/31.03 Ennio Tasciotti, Houston, TX (US); 2008/0280140 Al 11/2008 Ferrari et al. Jason Sakamoto, Houston, TX (US) FOREIGN PATENT DOCUMENTS (73) Assignees: Board of Regents of the University of EP 855179 7/1998 Texas System, Austin, TX (US); The WO WO 2007/120248 10/2007 Ohio State University Research WO WO 2008/054874 5/2008 Foundation, Columbus, OH (US) WO WO 2008054874 A2 * 5/2008 ............... A61K 8/11 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Akerman et al., "Nanocrystal targeting in vivo," Proc. Nad. Acad. Sci. USA, Oct. 1, 2002, 99(20):12617-12621. (21) Appl. No.: 14/725,570 Alley et al., "Feasibility of Drug Screening with Panels of Human tumor Cell Lines Using a Microculture Tetrazolium Assay," Cancer (22) Filed: May 29, 2015 Research, Feb.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • NPRC) VIP List, 2009
    Description of document: National Archives National Personnel Records Center (NPRC) VIP list, 2009 Requested date: December 2007 Released date: March 2008 Posted date: 04-January-2010 Source of document: National Personnel Records Center Military Personnel Records 9700 Page Avenue St. Louis, MO 63132-5100 Note: NPRC staff has compiled a list of prominent persons whose military records files they hold. They call this their VIP Listing. You can ask for a copy of any of these files simply by submitting a Freedom of Information Act request to the address above. The governmentattic.org web site (“the site”) is noncommercial and free to the public. The site and materials made available on the site, such as this file, are for reference only. The governmentattic.org web site and its principals have made every effort to make this information as complete and as accurate as possible, however, there may be mistakes and omissions, both typographical and in content. The governmentattic.org web site and its principals shall have neither liability nor responsibility to any person or entity with respect to any loss or damage caused, or alleged to have been caused, directly or indirectly, by the information provided on the governmentattic.org web site or in this file. The public records published on the site were obtained from government agencies using proper legal channels. Each document is identified as to the source. Any concerns about the contents of the site should be directed to the agency originating the document in question. GovernmentAttic.org is not responsible for the contents of documents published on the website.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0196409 A1 Da0 Et Al
    US 2005O1964O9A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0196409 A1 Da0 et al. (43) Pub. Date: Sep. 8, 2005 (54) COMPOSITIONS OF BOTANICAL (52) U.S. Cl. ....................... 424/195.15; 435/6; 435/723; EXTRACTS FOR TREATING 424/741; 424/746; 424/769; MALIGNANCYASSOCIATED CHANGES 702/20 (76) Inventors: James Dao, Henderson, NV (US); Jeffrey J. Dao, San Mateo, CA (US) Correspondence Address: (57) ABSTRACT MORRISON & FOERSTER LLP 755 PAGE MILL RD PALO ALTO, CA 94304-1018 (US) Methods for diagnosis of malignancy associated changes (MAC) using Automated Quantitative Cytometry (AQC) (21) Appl. No.: 10/949,178 and treatment using compositions, extracts and compounds comprising botanical extracts. Use of Such compounds in the (22) Filed: Sep. 24, 2004 prevention and therapy of cancer diagnosed by the AOC Related U.S. Application Data MAC test are also provided as well as methods for treatment using the compositions of this invention. Compositions (60) Provisional application No. 60/506,066, filed on Sep. comprising therapeutically effective amounts of two or more 24, 2003. of an extract of Ganoderma lucidum, an extract of Salvia miltiorrhiza and an extract of Scutellaria barbata and Publication Classification optionally a therapeutically effective amount of an extract of Hippophae rhamnoides are provided. Novel Synergistic (51) Int. Cl." ......................... A61K 35/84; A61K 35/78; effects of the use of these compounds in combination C12O 1/68; G01N 33/574; therapy are disclosed. Compositions further comprising G06F 19/00; G01N 33/48; therapeutically effective amounts of at least one chemothera GO1N 33/50 peutic agent are also provided.
    [Show full text]
  • WO 2018/096100 Al 31 May 2018 (31.05.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/096100 Al 31 May 2018 (31.05.2018) W !P O PCT (51) International Patent Classification: A61K 31/05 (2006.01) A61K 31/7068 (2006.01) A61K 31/164 (2006.01) A61K 33/24 (2006.01) A61K 31/352 (2006.01) A61K 45/06 (2006.01) A61K 31/473 {2006.01) A61P 21/00 (2006.01) A61K 31/5375 (2006.01) A61P 43/00 (2006.01) (21) International Application Number: PCT/EP2017/080353 (22) International Filing Date: 24 November 201 7 (24. 11.201 7) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 16200498.0 24 November 20 16 (24. 11.20 16) EP (71) Applicant: AOP ORPHAN PHARMACEUTICALS AG [AT/AT]; WilhelminenstraBe 91/11 f, 1160 Vienna (AT). (72) Inventors: KOHL, Agnes; WilhelminenstraBe 91/11 f, 1160 Vienna (AT). LENHARD, Ralf; WilhelminenstraBe 91/11 f, 1160 Vienna (AT). (74) Agent: LOD3L, Manuela et al; REDL Life Science Patent Attorneys, Donau-City-StraBe 11, 1220 Vienna (AT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]